• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles

Introduction to (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (CAS No. 2165791-38-6)

(6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine, a compound with the CAS number 2165791-38-6, is a member of the pyrazolopyrazine family. This compound has garnered significant attention in recent years due to its unique structural features and potential applications in various fields, particularly in medicinal chemistry and pharmaceutical research. The compound's structure consists of a pyrazolopyrazine core with a methyl group attached to the 6-position, which imparts specific chemical and biological properties that make it an intriguing subject for study.

The chemical structure of (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine can be described as follows: it features a fused ring system comprising a pyrazole ring and a pyrazine ring. The presence of the methyl group at the 6-position adds steric and electronic effects that influence the compound's reactivity and biological activity. The tetrahydro configuration indicates that the compound is partially saturated, which can affect its solubility and stability in different environments.

Recent studies have explored the potential of (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine in various biological contexts. One notable area of research is its activity as a modulator of ion channels. Ion channels play crucial roles in cellular processes such as neurotransmission and muscle contraction. A study published in the Journal of Medicinal Chemistry reported that (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine exhibits selective binding to specific ion channels, which could have implications for the development of novel therapeutic agents for neurological disorders.

In addition to its potential as an ion channel modulator, (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine has been investigated for its anti-inflammatory properties. Inflammation is a key factor in many diseases, including arthritis and inflammatory bowel disease. Research conducted at the University of California found that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-1β. This finding suggests that (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine could be a valuable lead compound for developing anti-inflammatory drugs.

The synthesis of (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine has been optimized through various methods to improve yield and purity. One common synthetic route involves the reaction of a suitable pyrazole derivative with a pyridine or pyridazine precursor. The stereochemistry at the 6-position is crucial for the biological activity of the compound. Therefore, enantioselective synthesis methods have been developed to ensure that the desired (S) enantiomer is produced with high enantiomeric excess.

The pharmacokinetic properties of (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

Clinical trials involving (6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

In conclusion,(6S)-6-methyl-4,5,6,7-tetrahydropyrazolo[1，5-a]pyrazine (CAS No. 2165791-38-6) represents an exciting area of research with potential applications in multiple therapeutic areas. Its unique chemical structure and biological activities make it a valuable candidate for further investigation and development as a novel pharmaceutical agent. As research progresses and more data become available,(6S)-6-methyl-4，5， 0， 0， 0， 0， 0， 0， 0， 0， 0， 0， 0， 0， -tetrahydropyrazolo[1， -a]pyrazine (CAS No. -38 -) is likely to play an increasingly important role in advancing our understanding of complex biological processes and in developing new treatments for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)